AstraZeneca shares Phase III eneboparatide data in HypoPT

AstraZeneca said late-breaking Phase III data from the CALYPSO trial showed its investigational drug eneboparatide met the study’s composite primary endpoint in adults with chronic hypoparathyroidism. At 24 weeks, 31.1% of treated patients achieved normal albumin-adjusted serum calcium while becoming independent from active vitamin D and oral calcium supplements, versus placebo, according to results presented May 12, 2026, at the European Congress of Endocrinology in Prague. AstraZeneca and Alexion described CALYPSO as the largest global trial conducted in adults with chronic hypoparathyroidism, and said additional findings through 52 weeks suggested improvements in symptom burden, physical function, kidney-related measures, and bone health. (drugs.com)

Why it matters: For veterinary professionals, this is a human rare endocrine story, not a companion animal therapeutic development. Still, it’s notable because it reflects continued investment in hormone-replacement strategies that aim to restore physiology rather than only manage downstream calcium levels. CALYPSO randomized patients 2:1 to eneboparatide or placebo, with a planned open-label extension after the blinded phase, and the program has been part of AstraZeneca’s rare disease pipeline since its acquisition of Amolyt Pharma. Industry coverage also flagged a potential caveat: immunogenicity remains an issue to watch as the company moves toward regulatory planning. (clinicaltrials.gov)

What to watch: Watch for a full peer-reviewed dataset, regulatory timing from AstraZeneca, and more clarity on safety, especially antibody findings and how the drug may stack up against other emerging hypoparathyroidism programs. (drugs.com)